Immunomodulatory treatments in epilepsy

Seminars in Pediatric Neurology

Volumn 21, Issue 3, 2014, Pages 232-237

  Melvin, Joseph J ^a   Huntley Hardison, H ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EFALIZUMAB; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TETRACYCLINE; TOPIRAMATE; VIGABATRIN;

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BENIGN CHILDHOOD EPILEPSY; BRAIN INFECTION; CEREBROVASCULAR ACCIDENT; DRESS SYNDROME; DRUG MEGADOSE; EPILEPSY; EPILEPTIC STATE; FEBRILE INFECTION RELATED EPILEPSY SYNDROME; FEVER; HEMIFACIAL ATROPHY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFANTILE SPASM; INFLAMMATORY DISEASE; INTRACTABLE EPILEPSY; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; LOW DRUG DOSE; LYMPHOCYTOPENIA; MESIAL TEMPORAL LOBE EPILEPSY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYOCLONUS SEIZURE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHODGKIN LYMPHOMA; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; RASH; RASMUSSEN SYNDROME; REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; SEIZURE THRESHOLD; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TEMPORAL LOBE EPILEPSY; TRAUMATIC BRAIN INJURY; UPPER RESPIRATORY TRACT INFECTION; WEST SYNDROME;

EID: 84916877125     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2014.08.001     Document Type: Review

References (51)

1. Kossoff E.H. Intractable childhood epilepsy: Choosing between the treatments. Semin Pediatr Neurol 2011, 18:145-149.
2. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
3. Irani S.R., Bien C.G., Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011, 24:146-153.
4. Gorter J.A., van Vliet E.A., Aronica E., et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006, 26:11083-11110.
5. Maroso M., Balosso S., Ravizza T., et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010, 16:413-419.
6. Zuliani L., Graus F., Giometto B., et al. Central nervous system neuronal surface antibody associated syndromes: Review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012, 83:638-645.
7. Kramer U., Chi C.S., Lin K.L., et al. Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome: A multicenter study on 77 children. Epilepsia 2011, 52:1956-1965.
8. Roberts D.J., Goralski K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008, 4:1245-1264.
9. Haberlandt E., Weger C., Sigl S.B., et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr Neurol 2010, 42:21-27.
10. Tolmacheva E.A., Oitzl M.S., G. Van Luijtelaar Stress glucocorticoids and absences in a genetic epilepsy model. Horm Behav 2012, 61:706-710.
11. Pachter J.S., De Vries H.E., Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003, 62:593-604.
12. Yu N., Liu H., Di Q. Modulation of immunity and the inflammatory response: A new target for treating drug-resistant epilepsy. Curr Neuropharmacol 2013, 11:114-127.
13. Brunson K.L., Khan N., Eghbal-Ahmadi M., et al. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. Ann Neurol 2001, 49:304-312.
14. Mackay M.T., Weiss S.K., Adams-Webber T., et al. Practice parameter: Medical treatment of infantile spasms: Report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004, 62:1668-1681.
15. Okumura A., Tsuji T., Kato T., et al. ACTH therapy for generalized seizures other than spasms. Seizure 2006, 15:469-475.
16. Gayatri N.A., Ferrie C.D., Cross H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst Rev 2007, CD005222.
17. Suleiman J., Brenner T., Gill D., et al. Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev Med Child Neurol 2011, 53:1058-1060.
18. Sloka J.S., Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005, 11:425-432.
19. Sevilla-Castillo R.A., Palacios G.C., Ramirez-Campos J., et al. Methylprednisolone for the treatment of children with refractory epilepsy. Neuropediatrics 2009, 40:265-268.
20. Wang D.D., Englot D.J., Garcia P.A., et al. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav 2012, 24:314-318.
21. Frenzel T., Lee C.Z., Kim H., et al. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: Pilot study of adverse events and tolerance. Cerebrovasc Dis 2008, 25:157-163.
22. Eibl M.M., Wedgwood R.J. Intravenous immunoglobulin: A review. Immunodefic Rev? 1989, (suppl 1):1-42.
23. Durandy A., Kaveri S.V., Kuijpers T.W., et al. Intravenous immunoglobulins-Understanding properties and mechanisms. Clin Exp Immunol 2009, 158(suppl 1):2-13.
24. Fois A., Vascotto M. Use of intravenous immunoglobulins in drug-resistant epilepsy. Childs Nerv Syst 1990, 6:400-405.
25. Pechadre J.C., Sauvezie B., Osier C., et al. The treatment of epileptic encephalopathies with gamma globulin in children (author's transl). Rev Electroencephalogr Neurophysiol Clin 1977, 7:443-447.
26. van Engelen B.G., Renier W.O., Weemaes C.M., et al. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 1994, 19:181-190.
27. Billiau A.D., Witters P., Ceulemans B., et al. Intravenous immunoglobulins in refractory childhood-onset epilepsy: Effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia 2007, 48:1739-1749.
28. Mikati M.A., Saab R., Fayad M.N., et al. Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. Pediatr Neurol 2002, 26:298-300.
29. Arts W.F., Aarsen F.K., Scheltens-de Boer M., et al. Landau-Kleffner syndrome and CSWS syndrome: Treatment with intravenous immunoglobulins. Epilepsia 2009, 50(suppl 7):55-58.
30. Villani F., Spreafico R., Farina L., et al. Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis. Neurology 2001, 56:248-250.
31. Georgieva Z., Parton M. Cerebellar ataxia and epilepsy with anti-GAD antibodies: Treatment with IVIG and plasmapheresis. BMJ Case Rep 2014, [Epub ahead of print] PMID 24419643.
32. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
33. Titulaer M.J., McCracken L., Gabilondo I., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013, 12:157-165.
34. Baroncini D., Spagnolo F., Sarro L., et al. A complex case of anti-GAD antibody-related syndrome treated with Rituximab. Neurol Sci 2013, 34:1847-1849.
35. Brown J.W., Martin P.J., Thorpe J.W., et al. Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. J Neuroimmunol 2014, 271:66-68.
36. Caraballo R.H., Reyes G., Avaria M.F., et al. Febrile infection-related epilepsy syndrome: A study of 12 patients. Seizure 2013, 22:553-559.
37. Miya K., Takahashi Y., Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev 2014, 36:645-652.
38. Krogias C., Hoepner R., Muller A., et al. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol 2013, 70:1056-1059.
39. Albensi B.C., Sullivan P.G., Thompson M.B., et al. Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol 2000, 162:385-389.
40. Jung S., Yang H., Kim B.S., et al. The immunosuppressant cyclosporin A inhibits recurrent seizures in an experimental model of temporal lobe epilepsy. Neurosci Lett 2012, 529:133-138.
41. Gopal A.K., Thorning D.R., Back A.L. Fatal outcome due to cyclosporine neurotoxicity with associated pathological findings. Bone Marrow Transplant 1999, 23:191-193.
42. Nishimura T., Imai H., Minabe Y., et al. Beneficial effects of FK506 for experimental temporal lobe epilepsy. Neurosci Res 2006, 56:386-390.
43. Suzuki K., Omura S., Ohashi Y., et al. FK506 facilitates chemical kindling induced by pentylenetetrazole in rats. Epilepsy Res 2001, 46:279-282.
44. Bien C.G., Tiemeier H., Sassen R., et al. Rasmussen encephalitis: Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 2013, 54:543-550.
45. Kanter I.C., Huttner H.B., Staykov D., et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008, 49:914-920.
46. Pacifici R., Zuccaro P., Iannetti P., et al. Immunologic aspects of vigabatrin treatment in epileptic children. Epilepsia 1995, 36:423-426.
47. Yehuda R., Yang R.K., Golier J.A., et al. Effect of topiramate on glucocorticoid receptor mediated action. Neuropsychopharmacology 2004, 29:433-439.
48. Beghi E., Shorvon S. Antiepileptic drugs and the immune system. Epilepsia 2011, 52(suppl 3):40-44.
49. Suleiman J., Brilot F., Lang B., et al. Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia 2013, 54:1036-1045.
50. Takahashi Y., Imai K., Ikeda H., et al. Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain Dev 2013, 35:236-244.
51. Toledano M., Britton J.W., McKeon A., et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2011, 82:1578-1688.